Amphion Innovations
Amphion Innovations develops and operates companies in the life sciences and medical technology sectors. Amphion works in partnership with universities and corporations seeking to commercialise intellectual property using its proven company creation and building process.
Turning IP into cash
Partner Companies performing well
DataTern subsidiary earning healthy revenues from IP enforcement
Despite good recent share performance, discount to NAV still too high given track record of asset growth
Publication Date:
November 16 2009
Portfolio performing well and revenues from IP
Unique process for commercialising IP Successful
20 year record; and NAV/share growth since IPO (2005) of 36% per annum ($), 28% (£)
Rigorous election process for investments, mitigating risk
Partner Companies performing well
Share price discount to reported NAV anomalous
Publication Date:
June 12 2008
Good results, but core strength is quality and value of portfolio
Revenues + 48%
NAV + 36%
Successful financings for Amphion and partner companies
Gulf initiative and IP entity formed
Shares trading barely above NAV gives significant potential upside
Publication Date:
September 18 2007
Amphion; Stock market still missing the point
- Positive trading update
- Strategic Gulf venture taps into rapidly growing market
- Myconostica: another UK addition to portfolio
- Significant realised gains on Beijing Med-Pharm
- 20 years of high NAV growth delivered by management
- Valued at a deep discount to peer group
Publication Date:
February 9 2007
Amphion; building a strong future
- Development and investment in life sciences/medtech
- Unique process for commercialising IP
- Proven record of success over 20 years
- Currently valued at deep discount to peer group (market cap/NAV multiple)
Publication Date:
March 13 2006